Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
TH-4000 is a pan-HER inhibitor prodrug, which is activated within hypoxic tumor conditions, potentially resulting in decreased proliferation of HER-expressing tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TH-4000||PR610|Hypoxin|Hypoxia-activated Prodrug TH-4000||EGFR Inhibitor (Pan) 47||TH-4000 is an EGFR tyrosine kinase inhibitor prodrug that is activated under hypoxic conditions, potentially leads to growth inhibition of EGFR-mutant tumor cells (PMID: 26811177).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01631279||Phase Ib/II||TH-4000||A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors||Terminated|
|NCT02449681||Phase II||TH-4000||Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS||Terminated|
|NCT02454842||Phase II||TH-4000||Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC||Terminated|